Reprogenetics

Experts in Preimplantation Genetic Diagnosis

TRUMBULL, Conn., June 1, 2016 – CooperSurgical a leading provider of women’s health care and Assisted Reproductive Technology (ART) solutions has acquired Reprogenetics UK of Oxford, United Kingdom. Reprogenetics UK is one of the preeminent genetics laboratories specializing in preimplantation screening (PGS) and preimplantation diagnosis (PGD) in Europe. Reprogenetics UK will maintain its close association with Reprogenetics, its US counterpart, while being folded into CooperSurgical’s formidable lineup of ART genetic testing companies which include Reprogenetics, Genesis Genetics (including its UK division) and newly acquired Recombine.

“Our new relationship with CooperSurgical will further enhance our world-leading research capabilities allowing us to deliver new technologies more rapidly and frequently than we could do on our own,” said Prof. Dagan Wells, PhD, FRCPath, Director of Reprogenetics UK. “Reprogenetics UK is a terrific addition to our industry leading ART portfolio of IVF and genetic testing solutions,” added Paul Remmell, President and CEO of CooperSurgical.

About CooperSurgical

Since our founding in 1990, CooperSurgical has researched, developed and manufactured a wide range of trusted brands that have advanced the standard of care for families. Our diversified portfolio of products and services focuses on women’s health, fertility, and diagnostics.

CooperSurgical Inc. is a wholly owned subsidiary of The Cooper Companies (NYSE: COO). The company, headquartered in Trumbull, CT produces and markets a wide array of products for use by women’s health care clinicians. More information can be found at www.coopersurgical.com.

About Reprogenetics

Reprogenetics, headquartered in Livingston, NJ is the world’s largest genetics laboratory specializing in preimplantation genetics screening (PGS) and preimplantation genetic diagnosis (PGD). PGS, which tests for the correct number of chromosomes, and PGD, which tests embryos for specific inherited disorders, have the potential to increase implantation rates and establish a pregnancy unaffected by specific known genetic characteristics. Reprogenetics offers the latest technology in comprehensive chromosome screening, routinely investigates the accuracy of new protocols, and performs randomized clinical trials with the next generation of technology while offering personalized service to its referring fertility centers and their patients worldwide. More information about Reprogenetics can be found at www.reprogenetics.com.